Abstract: A modified hemofiltration method for clearing peripheral ?-synuclein aggregates in patients with neurodegenerative diseases is provided, which falls into the field of medicine. Specifically, a ratio S of synuclein dimers in blood is obtained; a blood flow velocity and an exchange membrane area for hemofiltration are determined through clinical trial data or historical literature data; hemofiltration is performed by the determined blood flow velocity and exchange membrane area, a calculation model of the ratio S of different synuclein dimers and an exchange membrane aperture D required for hemofiltration is constructed by linear regression; a clearance rate of synuclein dimers can be estimated by setting hemofiltration parameters with the calculation model. It is found that hemofiltration is beneficial to reducing the level of peripheral ?-synuclein aggregates in patients with neurodegenerative diseases.

Abstract: A kit for quiescent detecting alpha-synuclein aggregates is provided by the present application, relating to the field of biotechnology. The kit includes recombinant monomeric alpha-synuclein, ammonium sulfate and thioflavine T. The incubation conditions are modified in this application, allowing the detection of pre-formed fibrils diluted to 10 picogram per milliliter for the first time, with 1 microliter of sample translating to a total of 10 fg of pre-formed fibrils detected, with a sensitivity of fg level in a single cycle.

Abstract: A modified hemofiltration method for clearing peripheral ?-synuclein aggregates in patients with neurodegenerative diseases is provided, which falls into the field of medicine. Specifically, a ratio S of synuclein dimers in blood is obtained; a blood flow velocity and an exchange membrane area for hemofiltration are determined through clinical trial data or historical literature data; hemofiltration is performed by the determined blood flow velocity and exchange membrane area, a calculation model of the ratio S of different synuclein dimers and an exchange membrane aperture D required for hemofiltration is constructed by linear regression; a clearance rate of synuclein dimers can be estimated by setting hemofiltration parameters with the calculation model. It is found that hemofiltration is beneficial to reducing the level of peripheral ?-synuclein aggregates in patients with neurodegenerative diseases.